Trial · NCT04000165
Results by group84
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 84
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number Participants With Most Common Reported Drug Related Adverse Events | AG-348 in Participants With Sickle Cell Disease | Insomnia | 6 | Participants | |
| Number Participants With Most Common Reported Drug Related Adverse Events | AG-348 in Participants With Sickle Cell Disease | Arthralgia | 3 | Participants | |
| Number Participants With Most Common Reported Drug Related Adverse Events | AG-348 in Participants With Sickle Cell Disease | Hypertension | 3 | Participants | |
| Number Participants With Serious Adverse Events That Were Possibly Drug-related Serious Adverse Events | AG-348 in Participants With Sickle Cell Disease | 2 | Participants | ||
| Number Participants With Increase of ≥ 1 g/dL in Hemoglobin | AG-348 in Participants With Sickle Cell Disease | 9 | Participants | ||
| Change in Hemoglobin at Each Dose Level of AG-348 | AG-348 in Participants With Sickle Cell Disease | Baseline | 8.73 | Standard Error 0.51 | g/dL |
| Change in Hemoglobin at Each Dose Level of AG-348 | AG-348 in Participants With Sickle Cell Disease | 5 mg dose of AG-348 | 0.34 | Standard Error 0.22 | g/dL |
| Change in Hemoglobin at Each Dose Level of AG-348 | AG-348 in Participants With Sickle Cell Disease | 20 mg dose AG-348 | 0.76 | Standard Error 0.22 | g/dL |
| Change in Hemoglobin at Each Dose Level of AG-348 | AG-348 in Participants With Sickle Cell Disease | 50 mg dose AG-348 | 1.19 | Standard Error 0.22 | g/dL |
| Change in Hemoglobin at Each Dose Level of AG-348 | AG-348 in Participants With Sickle Cell Disease | 100 mg dose AG-348 | 0.92 | Standard Error 0.26 | g/dL |
| Change in Hemoglobin at Each Dose Level of AG-348 | AG-348 in Participants With Sickle Cell Disease | End of Taper Dose AG-348 | 0.34 | Standard Error 0.22 | g/dL |
| Change in Hemoglobin at Each Dose Level of AG-348 | AG-348 in Participants With Sickle Cell Disease | End of Study AG-348 | 0.37 | Standard Error 0.22 | g/dL |
| Change in Lactic Acid Dehydrogenase (LDH) at Each Dose Level of AG-348 | AG-348 in Participants With Sickle Cell Disease | Baseline | 348.4 | Standard Error 51.21 | U/L |
| Change in Lactic Acid Dehydrogenase (LDH) at Each Dose Level of AG-348 | AG-348 in Participants With Sickle Cell Disease | 5 mg dose of AG-348 | -7.81 | Standard Error 27.81 | U/L |
| Change in Lactic Acid Dehydrogenase (LDH) at Each Dose Level of AG-348 | AG-348 in Participants With Sickle Cell Disease | 20 mg dose AG-348 | -39.94 | Standard Error 27.81 | U/L |
| Change in Lactic Acid Dehydrogenase (LDH) at Each Dose Level of AG-348 | AG-348 in Participants With Sickle Cell Disease | 50 mg dose AG-348 | -25.31 | Standard Error 27.81 | U/L |
| Change in Lactic Acid Dehydrogenase (LDH) at Each Dose Level of AG-348 | AG-348 in Participants With Sickle Cell Disease | 100 mg dose AG-348 | -37.89 | Standard Error 34.95 | U/L |
| Change in Lactic Acid Dehydrogenase (LDH) at Each Dose Level of AG-348 | AG-348 in Participants With Sickle Cell Disease | End of Taper Dose AG-348 | 20.63 | Standard Error 28.35 | U/L |
| Change in Lactic Acid Dehydrogenase (LDH) at Each Dose Level of AG-348 | AG-348 in Participants With Sickle Cell Disease | End of Study AG-348 | 30.72 | Standard Error 28.34 | U/L |
| Change in Total Bilirubin at Each Dose Level of AG-348 | AG-348 in Participants With Sickle Cell Disease | Baseline | 1.82 | Standard Error 0.28 | mg/dL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04000165/results